Multifunctional cell microcarriers for high throughput cell culture and enzyme-free cell harvesting

用于高通量细胞培养和无酶细胞收获的多功能细胞微载体

• 批准号: 513318-2017
• 负责人: Akbari, Mohsen
• 金额: $ 3.26万
• 依托单位: University of Victoria
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=688830
• 关键词: Multifunctional; cell; microcarriers; throughput; culture

RepliCel is a regenerative medicine company that develops autologous cell therapies to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. The cells in this technology are isolated from skin biopsies that are obtained from patients, cultured in two-dimensional flasks for up to a month and a half, harvested using enzymes, and delivered in the patients using RepliCel's proprietary, next-generation injection device. Recently, the successful completion of its first-in-human clinical study of the Company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness) was reported. As such, RepliCel seeks novel technologies to improve their cell culture process, which is currently time-consuming, labor-intensive, and low-throughput. The overarching goal of this collaborative research and development proposal is to develop an innovative platform that enables culturing a large number of adherent cells in small volumetric footprints is imperative for meeting lot requirements at different scales. In this project, we will use a multifaceted approach that combines microfluidic technology, advanced materials, and drug delivery to grow cells in large quantities and harvest them without using cell-destructive enzymes. This technology will allow RepliCel to compete in the ever-increasing market of cell therapy approaches for the treatment of chronic tendinosis, damaged or aged skin, and pattern baldness. The proposed research is anticipated to result in significant economic gains for BC and Canada since the targeted technology applies to an emerging and strategic market. Innovations in this area can help reducing the costs associated with current cell-based treatment and transform the health and life sciences sectors.

Cel是一家再生医学公司，开发自体细胞疗法来治疗慢性肌腱病、紫外线损伤或老化皮肤以及模式脱发。这项技术中的细胞是从患者的皮肤活检中分离出来的，在二维烧瓶中培养长达一个半月，使用酶收获，并使用dcel专有的下一代注射装置输送到患者体内。最近，成功完成了其第一次在人体临床研究的公司的自体细胞疗法治疗雄激素性脱发（模式脱发）的报告。因此，<$Cel寻求新的技术来改善他们的细胞培养过程，这是目前耗时，劳动密集型和低通量。这项合作研发提案的总体目标是开发一种创新平台，能够在小体积占地面积中培养大量贴壁细胞，这对于满足不同规模的批次要求至关重要。在这个项目中，我们将使用一种多方面的方法，将微流体技术、先进材料和药物输送相结合，在不使用破坏细胞的酶的情况下大量培养细胞并收获它们。这项技术将使<$Cel能够在不断增长的细胞治疗市场中竞争，用于治疗慢性肌腱病，受损或老化的皮肤和模式脱发。拟议的研究预计将为不列颠哥伦比亚省和加拿大带来重大的经济收益，因为目标技术适用于新兴的战略市场。该领域的创新可以帮助降低与当前细胞治疗相关的成本，并改变健康和生命科学领域。